Re-engineered honey has proved to be a novel and successful development for Matoke Pharma, as well as a crucial step on the UK biotech company’s plans to target antimicrobial resistance (AM
The UK government has published a new five year plan aimed at tackling antimicrobial resistance (AMR), including a new NHS reimbursement scheme backed by NICE to encourage pharma to develop
GPs being sent warning letters and the World Health Organization’s World Vaccinations Week have brought the spectre of antimicrobial resistance (AMR) back into the headlines of late.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.